Jump to main content
Jump to site search

Issue 11, 2019
Previous Article Next Article

A platinum(iv) prodrug to defeat breast cancer through disrupting vasculature and inhibiting metastasis

Author affiliations

Abstract

A PtIV prodrug (PDMA) exhibits great potential for the therapy of metastatic triple-negative breast cancer (TNBC) through a synergistic action of antiangiogensis and antimetastasis.

Graphical abstract: A platinum(iv) prodrug to defeat breast cancer through disrupting vasculature and inhibiting metastasis

Back to tab navigation

Supplementary files

Article information


Submitted
24 Jan 2019
Accepted
13 Feb 2019
First published
14 Feb 2019

Dalton Trans., 2019,48, 3571-3575
Article type
Communication

A platinum(IV) prodrug to defeat breast cancer through disrupting vasculature and inhibiting metastasis

Y. Guo, S. Zhang, H. Yuan, D. Song, S. Jin, Z. Guo and X. Wang, Dalton Trans., 2019, 48, 3571 DOI: 10.1039/C9DT00335E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.


Social activity

Search articles by author

Spotlight

Advertisements